The Claim
In adults with type 2 diabetes and obesity, administration of bimagrumab increases lean mass by 3.6% and reduces fat mass, a dual effect distinct from typical weight-loss interventions that result in lean mass loss.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes and obesity, bimagrumab increases lean body mass by 3.6% and decreases fat mass, whereas most weight-loss treatments reduce both fat and lean mass.
See the scientific wording
In adults with type 2 diabetes and obesity, bimagrumab increases lean mass by 3.6% while simultaneously reducing fat mass, a unique effect that contrasts with typical weight-loss interventions that cause lean mass loss.
A drug blocks a receptor that normally stops muscle growth and keeps fat cells inactive. This allows muscles to get bigger and fat cells to burn more energy, leading to more muscle and less fat at the same time.
What the research says
1 studyStudy: Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity
In people with type 2 diabetes and extra weight, a drug called bimagrumab helped them gain muscle and lose fat at the same time — which is rare because most diets or exercise programs make you lose muscle along with fat.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.